(Q36960092)

17 August 2017

1 reference

title

Combination antifungals: an update (English)

1 reference

17 August 2017

Brahm H Segal

1

1 reference

17 August 2017

William J Steinbach

series ordinal

2

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Expert Review of Anti-infective Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

883-892

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Current approaches to diagnosis and treatment of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Interactions of posaconazole and flucytosine against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Treatment of Candida albicans endocarditis: case report and a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

A New Nonlinear Mixture Response Surface Paradigm for the Study of Synergism: A Three Drug Example

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Coping with stress: calmodulin and calcineurin in model and pathogenic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Calcineurin is essential for Candida albicans survival in serum and virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Calcineurin is required for virulence of Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Heat shock proteins as vaccine adjuvants in infections and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Immunotherapy for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.883

21 January 2018

Identifiers

DOI

10.1586/14787210.5.5.883

1 reference

17 August 2017

1 reference